Aarhus University Seal

Aarhus Immunotherapy Symposia

A Decade of Discovery: Celebrating Collaboration at the 10th Aarhus Immunotherapy Symposium

  • Paul Peter Tak, Candel Therapeutics, Boston, US (Keynote): Off-the-shelf product, individualized anti-tumor immune response: Reprogramming the immune system by viral immunotherapy for the treatment of solid tumors
  • Johanne Tracey Jacobsen, Oslo University, NO: Germinal center guided design of therapeutic monoclonal antibodies
  • Sophia Karagiannis, King’s College London & Epsilogen Ltd, UK: AllergoOncology: IgE immunotherapy to activate immune responses against solid tumours
  • Petra Bacher, Universitätsklinikum Schleswig-Holstein and Christian-Albrechts Universität , Kiel, DE: T cell mechanisms in Autoimmunity & Allergy
  • Boe Sandahl Sørensen, Aarhus University and Aarhus University Hospital, DK: Circulating DNA as Biomarkers in Cancer
  • Inge Marie Svane, Herlev University Hospital, DK: Reaching beyond checkpoint inhibitors to defeat cancer by immunotherapy
  • Christian Klein, Roche, Basel: Targeting CD20 with monoclonal/bispecific antibodies and combination therapy
  • Eric Vivier, Innate Pharma, FR:  Harnessing innate immunity in cancer therapy and beyond
  • Nicola Ferrari, AstraZeneca, UK: CAR-T in autoimmune disease

Previous symposia

9th Aarhus Immunotherapy Symposium (AIS9)

Breaking Barriers with Immunotherapy: From Bench to Bedside

13:00 – 14:00 registration, networking

13:50 – 14:00 Welcome and house rules: Thomas Vorup-Jensen

Chairs: Poul Sørensen, Martin Thomsen

14:00 – 14:30 Paul Eggleton, Revolo Biotherapeutics, New Orleans, USA. Therapeutic chaperones IRL201104 & IRL201805: returning out of balance immune systems to a normal state in inflammatory diseases

14:30 – 15:00 Göran Forsberg, Cantargia, Lund, Sweden: Antibody targeting of IL1RAP for treatment of cancer and inflammatory disease

15:00 – 15:30 Christian L. Hvas, Aarhus University, Aarhus, Denmark: Faecal microbiota transplantation: restoring intestinal immunotolerance

15:30 – 16:30 networking & coffee

Chairs: Hans Jürgen Hoffmann, Søren Degn

16:30 – 17:00 Anton Lindquist, Diamyd Medical, Stockholm, Sweden: Can parenteral administration of the autoantigen GAD65 induce tolerance and preserve beta cell function in type 1 diabetes?

17:00 – 17:30 Margriet J Velvoordeldonk, Galvani Bioelectronics, Stevenage, UK: Targeted splenic neuromodulation – the new frontier in therapies for autoimmune diseases

17:30 – 18:00 Alexander Scheffold, Christian-Albrechts-Universität, Kiel, Germany: Antigen-specific regulation of tolerance versus immune pathology in humans

18:00 – 18:30 Julie Rask Larsen, ALK, Hørsholm, Denmark: Real-world long-term effectiveness of allergen immunotherapy

18:30 – 20:30 Networking dinnertoire

The meeting is sponsored by companies from the pharmaceutical industry and major purveyors of scientific equipment


8th Aarhus Immunotherapy Symposium (AIS8)

AIS8: Immunotherapy in the service of medicine

Thursday 24. November 2022, 13:00-20:00
Aula, Aarhus University


  • Bent W. Deleuran, Aarhus University, DK:  Galectins determine the outcome for 4-1BB metabolism in rheumatoid arthritis
  • Catharien Hilkens, Newcastle University, UK: Dendritic cell-based tolerogenic therapies for rheumatoid arthritis
  • Azza Ahmed Khalil, Aarhus University Hospital, DK: How immunotherapy changed the treatment of lung cancer
  • Philippe Moingeon, Servier, FR  AI-driven drug development against autoimmune diseases
  • Laurent Mascarell, Stallergenes, FR: The role of biomarkers in precision medicine for house dust mite allergy

Coffee and networking


  • Markus Ollert, Luxembourg Inst. of Health, L: Early differential regulation of global immune signatures during venom and pollen allergen-specific immunotherapy.
  • Pieter Roitters, ActoBio, BE: ActoBiotics - A new class of bacteria-based therapeutic agents designed to modulate the body’s immune system towards antigen-specific immune tolerance

Cocktail dinatoire


7th Aarhus Immunotherapy Symposium (AIS7)

AIS7: Looking to the future of immunotherapies

Thursday November 25th, 1:00-8:00 PM

Aulaen (Bldg. 1412), Ndr. Ringgade, Aarhus University

2:00-3:40 pm

  • José Carballido, Novartis, Basel, CH (Keynote)
    Immune Tolerance: A backward glance into the future
  • Martin R. Jakobsen, UNIKUM, Aarhus, DK
    Plasmacytoid dendritic cells for use in cellular therapies
  • Antoon van Oosterhout, Imcyse, Liege, BE
    Bench-to-bedside: Imotope™-based antigen-specific immunotherapy forautoimmune diseases

-Networking & Coffee-

4:30-6:30 pm

  • Peter J. Holst, InProTher, Copenhagen, DK
    Active Immunotherapies targeting cancer associated endogenous retroviruses
  • Marina Romero-Ramos, Aarhus University, Aarhus, DK
    Monocyte changes during Parkinson’s Disease
  • Bjarke Hviid-Vyff, Aarhus University Hospital, Aarhus, DK
    Intralymphatic Immunotherapy: An innovative treatment of grass pollen allergy
  • Stefan Vieths, Paul-Ehrlich-Institute, Langen, DE
    Regulatory requirements for Allergen Immunotherapy Products in the European Union

-Networking and Cocktail dinatoire-

6th Aarhus Immunotherapy Symposium (AIS6)

AIS6: New insights and therapies for immunological diseases

Thursday November 26th 2020, 3:00-6:30 PM CET 


3:00-4:00 pm CET 

Solange Peters, Lausanne University, Lausanne, CH: 

“Promises and limitations of immunotherapy for lung cancer” 

Malte Peters, Morphosys AG, Munich, DE: 

“Modern drug development using real world data approaches” 


4:15-5:45 pm CET 

Mario Ehlers, Boehringer Ingelheim, Ridgefield, US: 

“T cell exhaustion as a therapeutic strategy in autoimmunity” 

Stinne Greisen, Aarhus University, Aarhus, DK: ”Co-inhibitory receptors in arthritic conditions - their relation to disease activity and tissue preservation” 

Michael Ehrenstein, University College London, London, UK: ”Anti-TNF was the first regulatory T cell targeted therapy for rheumatoid arthritis” 


6:00-7:00 pm CET 

Adam Sander, AdaptVac, Copenhagen, DK: “Development of a COVID-19 vaccine based on virus-like particles displaying the SARS-CoV-2 receptor-binding domain” 

Stephen Durham, Imperial College, London, UK: “New indications for allergen immunotherapy” 

5th Aarhus Immunotherapy Symposium (AIS5)

AIS5: New insights and unexplored opportunities of Immunotherapy

Thursday November 28th, 2019 13:00-20:00 

Lake Side Lecture Theatres, Aarhus University, Aarhus, Denmark 

All talks 20 min + 10 min discussion 

13:00 - 14:00 registration & networking 

Session 1 

Chairs: Thomas Vorup-Jensen & Poul Sørensen 

Simon Davis, University of Oxford, UK (Keynote) 

14:00 - 14:40 Leveraging immune receptor signalling - new routes to therapeutic intervention 

Søren Paludan, Aarhus University, DK 

14:40 - 15:10 Modulation of lupus disease by targeting the STING pathway 

Philippe Moingeon, Servier, Suresnes, FR 

15:10 - 15:40 Molecular stratification of patients with autoimmune diseases: applications to new treatment development 

15:45 - 16:45 Coffee 

Session 2 

Chairs: Hans Jürgen Hoffmann & Philippe Moingeon 

Eric Vivier, Innate Pharma, Marseille, FR 

16:45 – 17:15 Targeting innate immunity in cancer 

Allan Jensen, Lundbeck, Valby, DK 

17:15 - 17:45 Active immunization for treatment or prevention of neurodegenerative diseases 

Georg du Toit, Kings College, London, UK 

17:45-18:15 Recent advances in the prevention of food allergy 

Networking and cocktail dinatoire 18:30 – 20:00 

Sign-up participants and sponsors: events.au.dk/AIS5 

4th Aarhus Immunotherapy Symposium (AIS4)

AIS4: Translational immunotherapy – crossing boundaries

Aarhus University: Thursday November 29th, 2018 13:00-22:00 

All talks 20 min + 10 min discussion

13:30 - 14:00 registration & networking

Welcome:  Dean, Faculty of Health, Aarhus University 

Chairs: Thomas Vorup-Jensen & Georg Holländer

Bernard Malissen, CIML, Marseille, FR (Keynote)

14:00 - 14:40 In the LEGO box of the TCR system ... from the list of parts to the assembly instructions!

Rikard Holmdahl, Karolinska Institutet, Stockholm, SE

14:40-15:10 How autoreactive lymphocytes learn about tissue specific antigens in cartilage

Søren Degn, Aarhus University, DK

15:10 - 15:40 Beyond antibodies – pleiotropic functions of B cells in autoimmune disease

Birgitte Ursø, LEO Pharma, Ballerup, DK

15:40 - 16:10 Translational drug discovery in biologics from early discovery to clinical testing

16:10 - 16:30 Pause 20 min, coffee

Chairs: Hans-Jürgen Hoffmann & Poul Sørensen

Georg Holländer, Univ. of Oxford, UK

16:30 – 17:00 Deconstructing the thymus: Molecular insight into thymus development and function

Eva Pålsson-McDermott, Trinity College, Dublin, IRL

17:00 - 17:30 The role of metabolic reprogramming in macrophage effector function

Peter S. Andersen, ALK, Hørsholm, DK

17:30-18:00 Antibody repertoire development during sublingual allergy immunotherapy 

Mo Shamji, Imperial College, London, UK

18:00-18:30 Peptide allergen immunotherapy: Ready for prime time

Networking and cocktail dinatoire 18:30 – 20:00

3rd Aarhus Immunotherapy Symposium (AIS3)

AIS3: Translational cancer immunotherapy – new biomarkers, targets and combinations

Aarhus University: Thursday November 30st, 2017 13:00-18:00

All talks 20 min + 10 min discussion

13:30 - 14:00 registration & networking

Welcome:  Ole Steen Nielsen, Vice-Dean, Faculty of Health, Aarhus University

Chairs: Thomas Vorup-Jensen & Poul Sørensen

John Haurum, F-star, Cambridge, UK (Keynote)

14:00 - 14:40 Immuno-oncology: Revolutionizing cancer care

José Moreira, Copenhagen University, Denmark

14:40-15:10 Biomarkers for patient risk stratification: a rational approach to cancer prevention

Martin R. Jakobsen, Aarhus University, Denmark

15:10 - 15:40 Triggering the innate immune system: a novel approach to tumour remission

Per thor Straten, University Hospital Herlev, Denmark

15:40 - 16:10 Therapy of solid cancers using T cells and running shoes 

16:10 - 16:30 Pause 20 min, coffee 

Ivan Horak, Symphogen, Lyngby, Denmark

16:30 – 17:00 Precision medicine in the era of targeted therapy; from clinic back to bench

Ida Hiemstra, Genmab, Utrecht, Holland

17:00 - 17:30 Translating basic science to antibody therapeutics

Bent Jakobsen, Immunocore, Oxford, UK

17:30-18:00 Fine-tuned T cell receptors for cancer immunotherapy

Networking and dinner   18:00 – 22:00

2nd Aarhus Immunotherapy Symposium (AIS2)

AIS2: Autoimmunity - Restoring the Balance

Information about AIS2

1st Aarhus Immunotherapy Symposium (AIS1)

AIS1: A Christmas Symposium: The Gifts of Allergen Immunotherapy

Thursday 3 December 2015 14:00 - 19:00 

Merete Barker Aud., The Lakeside Lecture Theatres, Bartholins Allé 3, 8000 Aarhus C  

14:00 - 14:30 Registration & networking 

All talks 20 min + 5 min discussion 

Session 1: AIT State-of-the-Art 

Chairs: Hans Jürgen Hoffmann, Aarhus University & Hospital; Poul Sørensen, Stallergenes Greer & Aarhus University; Steffen Thiel, Aarhus University 

14:30 - 14:55 Allergen Immunotherapy Efficacy, safety and long term benefits. SCIT or SLIT? 

Prof. Stephen R. Durham, Imperial College London, UK 

14:55 - 15:20 Tolerance induction and prevention in allergy - a public health issue 

Prof. Erkka Valovirta, University of Turku, Turku, Finland 

15:20 - 15:45 Clinical Outcome Measures in AIT 

Prof. Oliver Pfaar, Heidelberg University & Center for Rhinology and Allergology, 

Wiesbaden, DE: 

15:45 - 16:10 Biomarkers of SLIT efficacy: a "panorOmic" view 

Dr. Philippe Moingeon, Stallergenes Greer, Paris, France 

16:10 - 16:35 Basophil Sensitivity and ISAC as Biomarkers for SCIT 

Dr. Johannes Schmid, Aarhus University, Denmark 

16:35 - 17:00 Coffee break and networking 

Session 2: Emerging new AIT approaches 

Chairs: Hans-Jørgen Malling, Gentofte Hospital, Hellerup; Edzard Spillner, Immunological Engineering, Aarhus University 

17:05 - 17:30 Targeting T cells with peptide immunotherapy 

Prof. Mark Larché, McMaster University, Hamilton, Ontario, Canada 

17:30 - 18:05 The good “COP”: AIT with <10% of the doses needed with extracts 

Dr. Kim Simonsen, Chief Development Officer, Anergis SA, Switzerland 

18:05 - 18:30 Introducing ILIT in Sweden 

Prof. Lars Olaf Cardell, Lund University & Karolinska Institute, Sweden 

18:30 - 19:00 A double-blind, placebo controlled trial to compare three and four injections in ILIT 

Dr. Søren Helbo, Aarhus University, Aarhus, Denmark 

19:15 Dinner and networking at ”Kemisk Kantine”, Langelandsgade 38, Bldg. 1510, 8000 Aarhus C